{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T14:07:01Z","timestamp":1786975621451,"version":"build-2736575974"},"reference-count":60,"publisher":"American Medical Association (AMA)","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Intern Med"],"published-print":{"date-parts":[[2025,7,1]]},"abstract":"\n Importance<\/jats:title>\n Long-acting muscarinic antagonists (LAMAs), such as tiotropium, are inhaled anticholinergic bronchodilators. However, there is limited clinical evidence examining whether LAMAs may have clinically meaningful central anticholinergic effects, such as increased dementia risk.<\/jats:p>\n <\/jats:sec>\n \n Objective<\/jats:title>\n To determine the association between tiotropium initiation and dementia risk in older adults with chronic obstructive pulmonary disease (COPD).<\/jats:p>\n <\/jats:sec>\n \n Design, Setting, and Participants<\/jats:title>\n \n This population-based, active-comparator, new-user cohort study used linkable administrative databases from Ontario, Canada, with a target trial emulation framework. The cohort included new users of tiotropium monotherapy or a long-acting \u03b2\n 2<\/jats:sub>\n -agonist plus inhaled corticosteroid (LABA-ICS) who were 66 years or older with COPD and without dementia, from September 4, 2004, to February 29, 2012. The follow-up period was up to 10 years from treatment initiation. Analyses were conducted from May 13, 2024, to March 6, 2025.\n <\/jats:p>\n <\/jats:sec>\n \n Exposures<\/jats:title>\n Tiotropium monotherapy initiators were compared with LABA-ICS initiators. The primary analysis used an intention-to-treat exposure definition.<\/jats:p>\n <\/jats:sec>\n \n Main Outcomes and Measures<\/jats:title>\n Incident dementia was determined using a validated algorithm. A 1-year lag time was implemented to mitigate reverse causality and to account for disease latency. Cause-specific hazard ratios (HRs) with death as a competing risk were obtained from Cox models with propensity score fine stratification weights. Weighted incidence rate differences (IRDs) per 1000 person-years were calculated.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n Among 30\u202f960 tiotropium monotherapy initiators and 19\u202f530 LABA-ICS initiators, the mean (SD) age was 75.1 (6.7) years and 46.7% were female. Over a median (IQR) follow-up period of 7.59 (3.91-10.0) years from treatment initiation, tiotropium monotherapy vs LABA-ICS initiation was associated with a small increase in dementia risk per 1000 person-years (incidence rates, 29.6 [95% CI, 28.8-30.4] vs 27.4 [95% CI, 26.4-28.3]; IRD, 2.3 [95% CI, 1.0-3.5]; HR, 1.09 [95% CI, 1.04-1.14]). The secondary as-treated analysis showed no significant association per 1000 person-years (incidence rates, 24.1 [95% CI, 22.2-26.0] vs 21.4 [95% CI, 18.5-24.3]; IRD, 2.7 [95% CI, \u22120.8 to 6.1]; HR, 1.11 [95% CI, 0.93-1.32]).<\/jats:p>\n <\/jats:sec>\n \n Conclusions and Relevance<\/jats:title>\n In this cohort study, among older adults with COPD, the small absolute rate increase in incident dementia associated with tiotropium monotherapy vs LABA-ICS was of questionable clinical importance, particularly when weighed against the established clinical benefits of tiotropium.<\/jats:p>\n <\/jats:sec>","DOI":"10.1001\/jamainternmed.2025.1251","type":"journal-article","created":{"date-parts":[[2025,5,19]],"date-time":"2025-05-19T11:31:33Z","timestamp":1747654293000},"page":"847","source":"Crossref","is-referenced-by-count":5,"title":["Tiotropium Initiation and Dementia Risk in Chronic Obstructive Pulmonary Disease"],"prefix":"10.1001","volume":"185","author":[{"given":"Che-Yuan","family":"Wu","sequence":"first","affiliation":[{"name":"Department of Pharmacology & Toxicology, University of Toronto, Toronto, Ontario, Canada"},{"name":"Dr. Sandra Black Centre for Brain Resilience and Recovery, Hurvitz Brain Sciences Program, Sunnybrook Research Institute, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tetyana","family":"Kendzerska","sequence":"additional","affiliation":[{"name":"ICES uOttawa, Ottawa, Ontario, Canada"},{"name":"Department of Medicine, Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada"},{"name":"Inflammation and Chronic Disease Program, The Ottawa Hospital Research Institute, Ottawa, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christa","family":"Wang","sequence":"additional","affiliation":[{"name":"ICES, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa Y.","family":"Xiong","sequence":"additional","affiliation":[{"name":"Department of Pharmacology & Toxicology, University of Toronto, Toronto, Ontario, Canada"},{"name":"Dr. Sandra Black Centre for Brain Resilience and Recovery, Hurvitz Brain Sciences Program, Sunnybrook Research Institute, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jodi D.","family":"Edwards","sequence":"additional","affiliation":[{"name":"ICES uOttawa, Ottawa, Ontario, Canada"},{"name":"University of Ottawa Heart Institute, University of Ottawa, Ottawa, Ontario, Canada"},{"name":"School of Epidemiology and Public Health, University of Ottawa, Ottawa, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter P.","family":"Liu","sequence":"additional","affiliation":[{"name":"University of Ottawa Heart Institute, University of Ottawa, Ottawa, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Refik","family":"Saskin","sequence":"additional","affiliation":[{"name":"ICES, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter","family":"Swardfager","sequence":"additional","affiliation":[{"name":"Department of Pharmacology & Toxicology, University of Toronto, Toronto, Ontario, Canada"},{"name":"Dr. Sandra Black Centre for Brain Resilience and Recovery, Hurvitz Brain Sciences Program, Sunnybrook Research Institute, Toronto, Ontario, Canada"},{"name":"KITE University Health Network Toronto Rehabilitation Institute, Toronto, Ontario, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"7","key":"ioi250023r1","doi-asserted-by":"publisher","first-page":"819","DOI":"10.1164\/rccm.202301-0106PP","article-title":"Global Initiative for Chronic Obstructive Lung Disease 2023 report: GOLD executive summary.","volume":"207","author":"Agust\u00ed","year":"2023","journal-title":"Am J Respir Crit Care Med"},{"issue":"5","key":"ioi250023r2","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1016\/j.chest.2023.08.014","article-title":"2023 Canadian Thoracic Society guideline on pharmacotherapy in patients with stable COPD.","volume":"164","author":"Bourbeau","year":"2023","journal-title":"Chest"},{"issue":"6","key":"ioi250023r3","doi-asserted-by":"publisher","first-page":"560","DOI":"10.1001\/archinternmed.2010.17","article-title":"Trends in chronic obstructive pulmonary disease prevalence, incidence, and mortality in Ontario, Canada, 1996 to 2007: a population-based study.","volume":"170","author":"Gershon","year":"2010","journal-title":"Arch Intern Med"},{"key":"ioi250023r4","doi-asserted-by":"publisher","DOI":"10.3389\/fnagi.2022.962562","article-title":"Risk of dementia or cognitive impairment in COPD patients: a meta-analysis of cohort studies.","volume":"14","author":"Wang","year":"2022","journal-title":"Front Aging Neurosci"},{"issue":"7","key":"ioi250023r5","doi-asserted-by":"publisher","first-page":"2052","DOI":"10.1111\/jgs.18372","article-title":"American Geriatrics Society 2023 updated AGS Beers Criteria\u00ae for Potentially Inappropriate Medication Use in Older Adults.","volume":"71","author":"2023 American Geriatrics Society Beers Criteria\u00ae Update Expert Panel","year":"2023","journal-title":"J Am Geriatr Soc"},{"issue":"22","key":"ioi250023r6","doi-asserted-by":"publisher","first-page":"2716","DOI":"10.1001\/archinte.163.22.2716","article-title":"Updating the Beers Criteria for Potentially Inappropriate Medication Use in Older Adults: results of a US consensus panel of experts.","volume":"163","author":"Fick","year":"2003","journal-title":"Arch Intern Med"},{"issue":"3","key":"ioi250023r7","doi-asserted-by":"publisher","first-page":"311","DOI":"10.2217\/1745509X.4.3.311","article-title":"Impact of anticholinergics on the aging brain: a review and practical application.","volume":"4","author":"Boustani","year":"2008","journal-title":"Aging Health"},{"issue":"1","key":"ioi250023r8","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1186\/s12877-018-0929-6","article-title":"An anticholinergic burden score for German prescribers: score development.","volume":"18","author":"Kiesel","year":"2018","journal-title":"BMC Geriatr"},{"issue":"7","key":"ioi250023r9","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1111\/ggi.13680","article-title":"Development of an Anticholinergic Burden Scale specific for Korean older adults.","volume":"19","author":"Jun","year":"2019","journal-title":"Geriatr Gerontol Int"},{"issue":"4","key":"ioi250023r10","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1517\/17425250902828337","article-title":"Biochemical properties, pharmacokinetics and pharmacological response of tiotropium in chronic obstructive pulmonary disease patients.","volume":"5","author":"Price","year":"2009","journal-title":"Expert Opin Drug Metab Toxicol"},{"issue":"3","key":"ioi250023r11","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1080\/08998280.2004.11927996","article-title":"Tiotropium (Spiriva): a once-daily inhaled anticholinergic medication for chronic obstructive pulmonary disease.","volume":"17","author":"Durham","year":"2004","journal-title":"Proc (Bayl Univ Med Cent)"},{"issue":"3","key":"ioi250023r12","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1038\/s43587-021-00043-5","article-title":"Healthy aging and the blood-brain barrier.","volume":"1","author":"Banks","year":"2021","journal-title":"Nat Aging"},{"issue":"8","key":"ioi250023r13","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1001\/jamainternmed.2019.0677","article-title":"Anticholinergic drug exposure and the risk of dementia: a nested case-control study.","volume":"179","author":"Coupland","year":"2019","journal-title":"JAMA Intern Med"},{"key":"ioi250023r14","doi-asserted-by":"publisher","first-page":"k1315","DOI":"10.1136\/bmj.k1315","article-title":"Anticholinergic drugs and risk of dementia: case-control study.","volume":"361","author":"Richardson","year":"2018","journal-title":"BMJ"},{"issue":"5","key":"ioi250023r15","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1093\/ije\/dyaa144","article-title":"Emulating a target trial in case-control designs: an application to statins and colorectal cancer.","volume":"49","author":"Dickerman","year":"2020","journal-title":"Int J Epidemiol"},{"issue":"4","key":"ioi250023r16","doi-asserted-by":"publisher","first-page":"488","DOI":"10.1097\/EDE.0b013e3181a819a1","article-title":"Overadjustment bias and unnecessary adjustment in epidemiologic studies.","volume":"20","author":"Schisterman","year":"2009","journal-title":"Epidemiology"},{"issue":"9","key":"ioi250023r17","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1093\/aje\/kwg231","article-title":"Evaluating medication effects outside of clinical trials: new-user designs.","volume":"158","author":"Ray","year":"2003","journal-title":"Am J Epidemiol"},{"issue":"3","key":"ioi250023r18","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1111\/jgs.18714","article-title":"Disease latency and new-user vs. prevalent-user cohort designs; implications for pharmacoepidemiology in dementia.","volume":"72","author":"Wu","year":"2023","journal-title":"J Am Geriatr Soc"},{"issue":"4","key":"ioi250023r19","doi-asserted-by":"publisher","DOI":"10.1183\/23120541.00013-2019","article-title":"Behavioural interventions targeting physical activity improve psychocognitive outcomes in COPD.","volume":"5","author":"Lavoie","year":"2019","journal-title":"ERJ Open Res"},{"issue":"8","key":"ioi250023r20","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.1164\/rccm.201706-1288OC","article-title":"Effect of bronchodilation, exercise training, and behavior modification on symptoms and physical activity in chronic obstructive pulmonary disease.","volume":"198","author":"Troosters","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"issue":"6","key":"ioi250023r21","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1016\/j.chest.2019.12.012","article-title":"Respiratory disease and lower pulmonary function as risk factors for dementia: a systematic review with meta-analysis.","volume":"157","author":"Russ","year":"2020","journal-title":"Chest"},{"key":"ioi250023r22","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.bbi.2023.02.009","article-title":"Lung function and risk of incident dementia: a prospective cohort study of 431,834 individuals.","volume":"109","author":"Ma","year":"2023","journal-title":"Brain Behav Immun"},{"issue":"15","key":"ioi250023r23","doi-asserted-by":"publisher","first-page":"1543","DOI":"10.1056\/NEJMoa0805800","article-title":"A 4-year trial of tiotropium in chronic obstructive pulmonary disease.","volume":"359","author":"Tashkin","year":"2008","journal-title":"N Engl J Med"},{"issue":"9696","key":"ioi250023r24","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.1016\/S0140-6736(09)61298-8","article-title":"Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial.","volume":"374","author":"Decramer","year":"2009","journal-title":"Lancet"},{"issue":"17","key":"ioi250023r25","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1001\/jama.2019.4973","article-title":"Effect of aclidinium bromide on major cardiovascular events and exacerbations in high-risk patients with chronic obstructive pulmonary disease: the ASCENT-COPD randomized clinical trial.","volume":"321","author":"Wise","year":"2019","journal-title":"JAMA"},{"issue":"4","key":"ioi250023r26","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1007\/s40471-015-0053-5","article-title":"The active comparator, new user study design in pharmacoepidemiology: historical foundations and contemporary application.","volume":"2","author":"Lund","year":"2015","journal-title":"Curr Epidemiol Rep"},{"issue":"7","key":"ioi250023r27","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/nrrheum.2015.30","article-title":"Active-comparator design and new-user design in observational studies.","volume":"11","author":"Yoshida","year":"2015","journal-title":"Nat Rev Rheumatol"},{"issue":"8","key":"ioi250023r28","doi-asserted-by":"publisher","first-page":"758","DOI":"10.1093\/aje\/kwv254","article-title":"Using big data to emulate a target trial when a randomized trial is not available.","volume":"183","author":"Hern\u00e1n","year":"2016","journal-title":"Am J Epidemiol"},{"key":"ioi250023r29","doi-asserted-by":"publisher","first-page":"70","DOI":"10.1016\/j.jclinepi.2016.04.014","article-title":"Specifying a target trial prevents immortal time bias and other self-inflicted injuries in observational analyses.","volume":"79","author":"Hern\u00e1n","year":"2016","journal-title":"J Clin Epidemiol"},{"issue":"6","key":"ioi250023r30","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1164\/rccm.200703-456SO","article-title":"Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary.","volume":"176","author":"Rabe","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"ioi250023r31","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1164\/rccm.201204-0596PP","article-title":"Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary.","volume":"187","author":"Vestbo","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"ioi250023r32","doi-asserted-by":"publisher","first-page":"315","DOI":"10.1080\/15412555.2022.2087616","article-title":"Prescription pathways from initial medication use to triple therapy in older COPD patients: a real-world population study.","volume":"19","author":"Jiang","year":"2022","journal-title":"COPD"},{"key":"ioi250023r33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.rmed.2018.08.001","article-title":"Trends in the utilisation of COPD therapeutic regimens before and after the introduction of LAMA\/LABA combination products: a population-based study.","volume":"143","author":"Parkin","year":"2018","journal-title":"Respir Med"},{"issue":"5","key":"ioi250023r34","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1080\/15412550903140865","article-title":"Identifying individuals with physcian diagnosed COPD in health administrative databases.","volume":"6","author":"Gershon","year":"2009","journal-title":"COPD"},{"issue":"18","key":"ioi250023r35","doi-asserted-by":"publisher","first-page":"856","DOI":"10.1212\/WNL.0000000000012777","article-title":"Applying propensity score methods in clinical research in neurology.","volume":"97","author":"Austin","year":"2021","journal-title":"Neurology"},{"issue":"6","key":"ioi250023r36","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1155\/2009\/963098","article-title":"Identifying patients with physician-diagnosed asthma in health administrative databases.","volume":"16","author":"Gershon","year":"2009","journal-title":"Can Respir J"},{"issue":"3","key":"ioi250023r37","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0173830","article-title":"Concurrent physician-diagnosed asthma and chronic obstructive pulmonary disease: a population study of prevalence, incidence and mortality.","volume":"12","author":"Kendzerska","year":"2017","journal-title":"PLoS One"},{"issue":"3","key":"ioi250023r38","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1002\/pds.1360","article-title":"Application of lag-time into exposure definitions to control for protopathic bias.","volume":"16","author":"Tamim","year":"2007","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"4","key":"ioi250023r39","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1097\/WAD.0b013e3181a6bebc","article-title":"Missed and delayed diagnosis of dementia in primary care: prevalence and contributing factors.","volume":"23","author":"Bradford","year":"2009","journal-title":"Alzheimer Dis Assoc Disord"},{"issue":"1","key":"ioi250023r40","doi-asserted-by":"publisher","first-page":"337","DOI":"10.3233\/JAD-160105","article-title":"Identification of physician-diagnosed Alzheimer\u2019s disease and related dementias in population-based administrative data: a validation study using family physicians\u2019 electronic medical records.","volume":"54","author":"Jaakkimainen","year":"2016","journal-title":"J Alzheimers Dis"},{"issue":"10","key":"ioi250023r42","first-page":"e392","article-title":"Identifying frail older people using predictive modeling.","volume":"18","author":"Sternberg","year":"2012","journal-title":"Am J Manag Care"},{"issue":"2","key":"ioi250023r43","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1097\/EDE.0000000000000595","article-title":"A propensity-score-based fine stratification approach for confounding adjustment when exposure is infrequent.","volume":"28","author":"Desai","year":"2017","journal-title":"Epidemiology"},{"key":"ioi250023r44","doi-asserted-by":"publisher","first-page":"l5657","DOI":"10.1136\/bmj.l5657","article-title":"Alternative approaches for confounding adjustment in observational studies using weighting based on the propensity score: a primer for practitioners.","volume":"367","author":"Desai","year":"2019","journal-title":"BMJ"},{"issue":"6","key":"ioi250023r45","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1161\/CIRCULATIONAHA.115.017719","article-title":"Introduction to the analysis of survival data in the presence of competing risks.","volume":"133","author":"Austin","year":"2016","journal-title":"Circulation"},{"issue":"1","key":"ioi250023r46","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1111\/bju.15040","article-title":"Increased risk of dementia among patients with overactive bladder treated with an anticholinergic medication compared to a beta-3 agonist: a population-based cohort study.","volume":"126","author":"Welk","year":"2020","journal-title":"BJU Int"},{"issue":"11","key":"ioi250023r47","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1002\/pds.5109","article-title":"Outcome misclassification: impact, usual practice in pharmacoepidemiology database studies and an online aid to correct biased estimates of risk ratio or cumulative incidence.","volume":"29","author":"Hall","year":"2020","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"5","key":"ioi250023r49","doi-asserted-by":"publisher","first-page":"291","DOI":"10.1002\/pds.1200","article-title":"Sensitivity analysis and external adjustment for unmeasured confounders in epidemiologic database studies of therapeutics.","volume":"15","author":"Schneeweiss","year":"2006","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"1","key":"ioi250023r50","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1164\/rccm.200707-973OC","article-title":"The prevention of chronic obstructive pulmonary disease exacerbations by salmeterol\/fluticasone propionate or tiotropium bromide.","volume":"177","author":"Wedzicha","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"issue":"11","key":"ioi250023r51","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1016\/S2213-2600(18)30368-0","article-title":"Comparative effectiveness of LABA-ICS versus LAMA as initial treatment in COPD targeted by blood eosinophils: a population-based cohort study.","volume":"6","author":"Suissa","year":"2018","journal-title":"Lancet Respir Med"},{"issue":"1","key":"ioi250023r52","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/15412555.2021.1877649","article-title":"Comparative effectiveness of initial LAMA versus LABA in COPD: real-world cohort study.","volume":"18","author":"Suissa","year":"2021","journal-title":"COPD"},{"issue":"12","key":"ioi250023r53","doi-asserted-by":"publisher","first-page":"1093","DOI":"10.1056\/NEJMoa1008378","article-title":"Tiotropium versus salmeterol for the prevention of exacerbations of COPD.","volume":"364","author":"Vogelmeier","year":"2011","journal-title":"N Engl J Med"},{"issue":"7","key":"ioi250023r54","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1016\/S2213-2600(13)70158-9","article-title":"Once-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): a randomised, blinded, parallel-group study.","volume":"1","author":"Decramer","year":"2013","journal-title":"Lancet Respir Med"},{"issue":"2","key":"ioi250023r55","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1016\/j.euf.2024.02.002","article-title":"Risks of dementia after treatment with an anticholinergic, beta-3 agonist, or combination of both for an overactive bladder: a Korean national cohort study.","volume":"10","author":"Park","year":"2024","journal-title":"Eur Urol Focus"},{"issue":"3","key":"ioi250023r56","doi-asserted-by":"publisher","first-page":"401","DOI":"10.1001\/jamainternmed.2014.7663","article-title":"Cumulative use of strong anticholinergics and incident dementia: a prospective cohort study.","volume":"175","author":"Gray","year":"2015","journal-title":"JAMA Intern Med"},{"key":"ioi250023r57","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.neubiorev.2021.04.031","article-title":"Anticholinergic drugs and the risk of dementia: a systematic review and meta-analysis.","volume":"127","author":"Zheng","year":"2021","journal-title":"Neurosci Biobehav Rev"},{"issue":"1","key":"ioi250023r58","doi-asserted-by":"publisher","DOI":"10.1002\/trc2.12095","article-title":"Targeting abnormal metabolism in Alzheimer\u2019s disease: the Drug Repurposing for Effective Alzheimer\u2019s Medicines (DREAM) study.","volume":"6","author":"Desai","year":"2020","journal-title":"Alzheimers Dement (N Y)"},{"issue":"3","key":"ioi250023r59","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1093\/aje\/kwae263","article-title":"Effect of different durations of treatment with antihypertensive drugs with anticholinergic effects on the risk of dementia: a target trial emulation study.","volume":"194","author":"Aguado","year":"2025","journal-title":"Am J Epidemiol"},{"key":"ioi250023r60","doi-asserted-by":"publisher","first-page":"1873","DOI":"10.2147\/COPD.S162646","article-title":"Inhaled glycopyrrolate for the treatment of chronic obstructive pulmonary disease.","volume":"13","author":"Tashkin","year":"2018","journal-title":"Int J Chron Obstruct Pulmon Dis"},{"key":"ioi250023r48","doi-asserted-by":"crossref","DOI":"10.1007\/978-0-387-87959-8","volume-title":"Applying Quantitative Bias Analysis to Epidemiologic Data","author":"Lash","year":"2009"},{"key":"ioi250023r41","unstructured":"R Core Team. R: a language and environment for statistical computing. 2021. Accessed April 7, 2025. https:\/\/www.r-project.org\/"}],"container-title":["JAMA Internal Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamainternalmedicine\/articlepdf\/2833830\/jamainternal_wu_2025_oi_250023_1751563216.14635.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,7]],"date-time":"2025-07-07T11:01:04Z","timestamp":1751886064000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamainternalmedicine\/fullarticle\/2833830"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,1]]},"references-count":60,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2025,7,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamainternmed.2025.1251","relation":{},"ISSN":["2168-6106"],"issn-type":[{"value":"2168-6106","type":"print"}],"subject":[],"published":{"date-parts":[[2025,7,1]]}}}